Christopher Logothetis

List of Publications by Year
in descending order

176	13,567	30070 54	23533 111
papers	citations	h-index	g-index

185	185	185	16225
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2014, 15, 700-712.	10.7	1,280
2	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. Journal of Clinical Oncology, 2016, 34, 1402-1418.	1.6	1,089
3	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nature Genetics, 2018, 50, 928-936.	21.4	652
4	Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2017, 35, 40-47.	1.6	577
5	Osteoblasts in prostate cancer metastasis to bone. Nature Reviews Cancer, 2005, 5, 21-28.	28.4	499
6	VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nature Medicine, 2017, 23, 551-555.	30.7	467
7	Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression. Cancer Discovery, 2016, 6, 80-95.	9.4	404
8	Aggressive Variants of Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2014, 20, 2846-2850.	7.0	339
9	Integrated Therapy for Locally Advanced Bladder Cancer: Final Report of a Randomized Trial of Cystectomy Plus Adjuvant M-VAC Versus Cystectomy With Both Preoperative and Postoperative M-VAC. Journal of Clinical Oncology, 2001, 19, 4005-4013.	1.6	284
10	Small cell carcinoma of the prostate part I a clinicopathologic study of 20 cases. Cancer, 1987, 59, 1803-1809.	4.1	269
11	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nature Genetics, 2021, 53, 65-75.	21.4	264
12	Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncology, The, 2012, 13, 1210-1217.	10.7	254
13	Altered Expression of Retinoblastoma Protein and Known Prognostic Variables in Locally Advanced Bladder Cancer. Journal of the National Cancer Institute, 1992, 84, 1256-1261.	6.3	246
14	PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 8403-8408.	7.1	226
15	Intense Androgen-Deprivation Therapy With Abiraterone Acetate Plus Leuprolide Acetate in Patients With Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant Study. Journal of Clinical Oncology, 2014, 32, 3705-3715.	1.6	220
16	Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers. Clinical Cancer Research, 2016, 22, 1520-1530.	7.0	206
17	Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer. European Urology, 2015, 67, 53-60.	1.9	205
18	Androgen receptor inhibitorâ€“induced â€œBRCAnessâ€•and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Science Signaling, 2017, 10, .	3.6	200

#	Article	IF	Citations
19	Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 11919-11924.	7.1	197
20	Cadherin-11 Promotes the Metastasis of Prostate Cancer Cells to Bone. Molecular Cancer Research, 2008, 6, 1259-1267.	3.4	162
21	Androgen receptorâ€“negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. Journal of Clinical Investigation, 2008, 118, 2697-710.	8.2	153
22	Chemotherapy for Small Cell Carcinoma of Prostatic Origin. Journal of Urology, 1992, 147, 935-937.	0.4	148
23	Differential Effects of Peptide Hormones Bombesin, Vasoactive Intestinal Polypeptide and Somatostatin Analog RC-160 on the Invasive Capacity of Human Prostatic Carcinoma Cells. Journal of Urology, 1993, 149, 1209-1213.	0.4	140
24	The management of brain metastases in germ cell tumors. Cancer, 1982, 49, 12-18.	4.1	134
25	Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene, 1999, 18, 1185-1196.	5.9	131
26	Molecular Classification of Prostate Cancer Progression: Foundation for Marker-Driven Treatment of Prostate Cancer. Cancer Discovery, 2013, 3, 849-861.	9.4	120
27	Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results. Journal of Clinical Oncology, 2015, 33, 1356-1363.	1.6	120
28	CXCL1 mediates obesity-associated adipose stromal cell trafficking and function in the tumour microenvironment. Nature Communications, 2016, 7, 11674.	12.8	118
29	Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Oncogene, 1998, 17, 2889-2899.	5.9	117
30	Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1â€“2 trial. Lancet Oncology, The, 2019, 20, 1432-1443.	10.7	115
31	Cadherin-11 Increases Migration and Invasion of Prostate Cancer Cells and Enhances their Interaction with Osteoblasts. Cancer Research, 2010, 70, 4580-4589.	0.9	113
32	Posttranslational regulation of Akt in human cancer. Cell and Bioscience, 2014, 4, 59.	4.8	111
33	Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study. Journal of Clinical Oncology, 2014, 32, 3391-3399.	1.6	110
34	Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Science Translational Medicine, 2020, 12, .	12.4	108
35	Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. European Urology, 2018, 73, 715-723.	1.9	105
36	Clinical stage i nonseminomatous and mixed germ cell tumors of the testis. A clinicopathologic study of 93 patients on a surveillance protocol after orchiectomy alone. Cancer, 1988, 62, 1202-1206.	4.1	102

#	Article	IF	Citations
37	Cisplatin, Cyclophosphamide and Doxorubicin Chemotherapy for Unresectable Urothelial Tumors: The M. D. Anderson Experience. Journal of Urology, 1989, 141, 33-37.	0.4	101
38	Brain metastasis from prostate carcinoma. Cancer, 1999, 86, 2301-2311.	4.1	96
39	Human prostate cancer model: Roles of growth factors and extracellular matrices. Journal of Cellular Biochemistry, 1992, 50, 99-105.	2.6	89
40	Surgery Following Response to Interfergn-Î±-Baseb Therapy for Residual Renal Cell Carcinoma. Journal of Urology, 1993, 149, 19-21.	0.4	89
41	Cyclophosphamide, Doxorubicin and Cisplatin Chemotherapy for Patients with Locally Advanced Urothelial Tumors with or without Nodal Metastases. Journal of Urology, 1985, 134, 460-464.	0.4	88
42	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nature Communications, 2018, 9, 2256.	12.8	88
43	Prostate cancer cellâ€“stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Science Translational Medicine, 2014, 6, 252ra122.	12.4	86
44	Growth-Inhibitory Effects of Serotonin Uptake Inhibitors on Human Prostate Carcinoma Cell Lines. Journal of Urology, 1995, 154, 247-250.	0.4	85
45	Model systems of prostate cancer: uses and limitations. Cancer and Metastasis Reviews, 1998, 17, 361-371.	5.9	83
46	Targeting Constitutively Activated Î²1 Integrins Inhibits Prostate Cancer Metastasis. Molecular Cancer Research, 2013, 11, 405-417.	3.4	83
47	Assessment of Luminal and Basal Phenotypes in Bladder Cancer. Scientific Reports, 2020, 10, 9743.	3.3	83
48	Spermatocytic seminoma with associated sarcoma of the testis. Cancer, 1988, 61, 409-414.	4.1	82
49	Targeting the MYCNâ€“PARPâ€“DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. Clinical Cancer Research, 2018, 24, 696-707.	7.0	80
50	Endothelial-to-Osteoblast Conversion Generates Osteoblastic Metastasis of Prostate Cancer. Developmental Cell, 2017, 41, 467-480.e3.	7.0	75
51	Neuroendocrine prostate cancer xenografts with largeâ€cell and smallâ€cell features derived from a single patient's tumor: Morphological, immunohistochemical, and gene expression profiles. Prostate, 2011, 71, 846-856.	2.3	68
52	Phase II trial of 5-fluorouracil, interferon-? and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer, 1997, 80, 2128-2132.	4.1	62
53	Multiplex protein detection on circulating tumor cells from liquid biopsies using imaging mass cytometry. Convergent Science Physical Oncology, 2018, 4, 015002.	2.6	60
54	Carcinoembryonic Antigen and Beta-Human Chorionic Gonadotropin as Serum Markers for Advanced Urothelial Malignancies. Journal of Urology, 1986, 136, 403-407.	0.4	54

#	Article	IF	Citations
55	Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature, 2022, 606, 797-803.	27.8	54
56	Hyperthyroidism in men with germ cell tumors and high levels of betaâ€human chorionic gonadotropin. Cancer, 1992, 69, 1286-1290.	4.1	53
57	Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 3776-3781.	7.1	53
58	The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development. Clinical Cancer Research, 2020, 26, 4933-4946.	7.0	53
59	Cyclophosphamide and Sequential Cisplatin for Advanced Seminoma: Long-Term Followup in 52 Patients. Journal of Urology, 1987, 138, 789-794.	0.4	50
60	Characterization of Patients with Androgen-Independent Prostatic Carcinoma Whose Serum Prostate Specific Antigen Decreased Following Flutamide Withdrawal. Journal of Urology, 1996, 155, 620-623.	0.4	50
61	Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer. Clinical Cancer Research, 2020, 26, 4143-4153.	7.0	50
62	Superimposed histologic and genetic mapping of chromosome 17 alterations in human urinary bladder neoplasia. Oncogene, 1997, 14, 2059-2070.	5.9	49
63	Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer. European Urology, 2019, 75, 44-60.	1.9	48
64	Orchiectomy in Advanced Germ Cell Cancer Following Intensive Chemotherapy: A Comparison of Systemic to Testicular Response. Journal of Urology, 1986, 136, 1221-1223.	0.4	47
65	Secretome Analysis of an Osteogenic Prostate Tumor Identifies Complex Signaling Networks Mediating Cross-talk of Cancer and Stromal Cells Within the Tumor Microenvironment. Molecular and Cellular Proteomics, 2015, 14, 471-483.	3.8	47
66	A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma. Cancer, 2000, 89, 615-618.	4.1	44
67	Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer. Clinical Cancer Research, 2016, 22, 107-121.	7.0	44
68	Understanding the Biology of Bone Metastases: Key to the Effective Treatment of Prostate Cancer. Clinical Cancer Research, 2008, 14, 1599-1602.	7.0	43
69	Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer. Cancer Research, 2015, 75, 4949-4959.	0.9	43
70	Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone. European Urology, 2019, 76, 418-424.	1.9	43
71	Intravital microscopy of osteolytic progression and therapy response of cancer lesions in the bone. Science Translational Medicine, 2018, 10, .	12.4	42
72	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. Nature Communications, 2021, 12, 1236.	12.8	40

#	Article	IF	Citations
73	Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer, 2016, 122, 1836-1843.	4.1	39
74	H3 ubiquitination by NEDD4 regulates H3 acetylation and tumorigenesis. Nature Communications, 2017, 8, 14799.	12.8	34
75	Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer. Scientific Reports, 2016, 6, 35354.	3.3	33
76	Primary Chemotherapy Followed by a Selective Retro Peritoneal Lymphadenectomy in the Management of Clinical Stage II Testicular Carcinoma: A Preliminary Report. Journal of Urology, 1985, 134, 1127-1130.	0.4	31
77	The Prostate Cancer Susceptibility Variant rs2735839 Near KLK3 Gene Is Associated with Aggressive Prostate Cancer and Can Stratify Gleason Score 7 Patients. Clinical Cancer Research, 2014, 20, 5133-5139.	7.0	31
78	Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis. Cell Reports, 2019, 26, 2241-2256.e4.	6.4	31
79	Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial.. Journal of Clinical Oncology, 2013, 31, LBA8-LBA8.	1.6	30
80	Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naÃ¯ve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment. , 2021, 9, e002919.		30
81	Disease reclassification risk with stringent criteria and frequent monitoring in men with favourableâ€risk prostate cancer undergoing active surveillance. BJU International, 2016, 118, 68-76.	2.5	27
82	Paired High-Content Analysis of Prostate Cancer Cells in Bone Marrow and Blood Characterizes Increased Androgen Receptor Expression in Tumor Cell Clusters. Clinical Cancer Research, 2017, 23, 1722-1732.	7.0	26
83	Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment. Clinical Cancer Research, 2021, 27, 3253-3264.	7.0	26
84	Mitochondrial DNA copy number in peripheral blood leukocytes and the aggressiveness of localized prostate cancer. Oncotarget, 2015, 6, 41988-41996.	1.8	26
85	Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis. Cell Reports, 2022, 39, 110595.	6.4	25
86	Aberrant expression of katanin p60 in prostate cancer bone metastasis. Prostate, 2012, 72, 291-300.	2.3	24
87	Epigenetics and prostate cancer: defining the timing of DNA methyltransferase deregulation during prostate cancer progression. Pathology, 2020, 52, 218-227.	0.6	24
88	MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nature Communications, 2022, 13, 1797.	12.8	23
89	Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancer. Oncology Letters, 2017, 13, 1949-1957.	1.8	22
90	Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer. Oncotarget, 2016, 7, 46321-46334.	1.8	22

#	Article	IF	Citations
91	Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends. Cancer, 2020, 126, 506-514.	4.1	21
92	Resistance to MET/VEGFR2 Inhibition by Cabozantinib Is Mediated by YAP/TBX5-Dependent Induction of FGFR1 in Castration-Resistant Prostate Cancer. Cancers, 2020, 12, 244.	3.7	21
93	Large Extracellular Vesicle Characterization and Association with Circulating Tumor Cells in Metastatic Castrate Resistant Prostate Cancer. Cancers, 2021, 13, 1056.	3.7	21
94	Androgen Receptor Signaling in Castration-Resistant Prostate Cancer Alters Hyperpolarized Pyruvate to Lactate Conversion and Lactate Levels In Vivo. Molecular Imaging and Biology, 2019, 21, 86-94.	2.6	20
95	Assessing Therapeutic Efficacy in Real-time by Hyperpolarized Magnetic Resonance Metabolic Imaging. Cells, 2019, 8, 340.	4.1	20
96	Radium 223-Mediated Zonal Cytotoxicity of Prostate Cancer in Bone. Journal of the National Cancer Institute, 2019, 111, 1042-1050.	6.3	20
97	P4HA2-induced prolyl hydroxylation suppresses YAP1-mediated prostate cancer cell migration, invasion, and metastasis. Oncogene, 2021, 40, 6049-6056.	5.9	19
98	Fibroblast growth factors signaling in bone metastasis. Endocrine-Related Cancer, 2020, 27, R255-R265.	3.1	19
99	The inhibition of the paracrine progression of prostate cancer as an approach to early therapy of prostatic carcinoma. Journal of Cellular Biochemistry, 1992, 50, 128-134.	2.6	18
100	Molecular regulation of cell death and therapeutic strategies for cell death induction in prostate carcinoma. Cancer and Metastasis Reviews, 1998, 17, 345-351.	5.9	18
101	Germ cell tumors in patients infected by the human immunodeficiency virus. Cancer, 2001, 92, 1460-1467.	4.1	18
102	Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. IScience, 2020, 23, 101201.	4.1	18
103	High-Grade Prostate Cancer and the Prostate Cancer Prevention Trial. Cancer Prevention Research, 2008, 1, 151-152.	1.5	17
104	Integrated Hedgehog signaling is induced following castration in human and murine prostate cancers. Prostate, 2013, 73, 153-161.	2.3	17
105	The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. Cancers, 2020, 12, 3254.	3.7	16
106	Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 532-541.	3.9	16
107	Oncogenic and osteolytic functions of histone demethylase NO66 in castration-resistant prostate cancer. Oncogene, 2019, 38, 5038-5049.	5.9	14
108	Decoding the evolutionary response to prostate cancer therapy by plasma genome sequencing. Genome Biology, 2020, 21, 162.	8.8	14

#	Article	IF	Citations
109	Leukocyte telomere length is associated with aggressive prostate cancer in localized prostate cancer patients. EBioMedicine, 2020, 52, 102616.	6.1	14
110	Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort. Journal of Urology, 2021, 206, 1147-1156.	0.4	14
111	Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies. Cancers, 2021, 13, 6022.	3.7	14
112	Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. Prostate Cancer and Prostatic Diseases, 2022, 25, 755-761.	3.9	14
113	Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. European Journal of Cancer, 2022, 170, 296-304.	2.8	14
114	The Correlation of Vinblastine Pharmacokinetics to Toxicity in Testicular Cancer Patients. Journal of Clinical Pharmacology, 1988, 28, 714-718.	2.0	13
115	Gemcitabine modulation of alkylator therapy. Cancer, 2001, 92, 194-199.	4.1	13
116	Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. JAMA Network Open, 2021, 4, e2122998.	5.9	13
117	Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel. Oncogene, 2021, 40, 6284-6298.	5.9	13
118	Targeting prostate cancer bone metastases. Cancer, 2003, 97, 785-788.	4.1	12
119	The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study. BMC Cancer, 2016, 16, 721.	2.6	12
120	Multiple pathways coordinating reprogramming of endothelial cells into osteoblasts by BMP4. IScience, 2021, 24, 102388.	4.1	12
121	Prostate tumor-induced stromal reprogramming generates Tenascin C that promotes prostate cancer metastasis through YAP/TAZ inhibition. Oncogene, 2022, 41, 757-769.	5.9	12
122	Workgroup 3: Current prognostic factors and their relevance to staging. , 1996, 78, 369-371.		11
123	Mitochondrial DNA copy number in peripheral blood leukocytes is associated with biochemical recurrence in prostate cancer patients in African Americans. Carcinogenesis, 2020, 41, 267-273.	2.8	11
124	A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-NaÃ¯ve Metastatic Prostate Cancer. Clinical Cancer Research, 2020, 26, 990-999.	7.0	11
125	The protein arginine methyltransferases (PRMTs) PRMT1 and CARM1 as candidate epigenetic drivers in prostate cancer progression. Medicine (United States), 2021, 100, e27094.	1.0	11
126	Results of subset analyses on overall survival (OS) from study CA184-043: Ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2014, 32, 2-2.	1.6	11

#	Article	IF	Citations
127	Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. European Urology Oncology, 2023, 6, 228-232.	5.4	11
128	Statins reduce castration-induced bone marrow adiposity and prostate cancer progression in bone. Oncogene, 2021, 40, 4592-4603.	5.9	10
129	Neoadjuvant apalutamide (APA) plus leuprolide (LHRHa) with or without abiraterone (AA) in localized high-risk prostate cancer (LHRPC).. Journal of Clinical Oncology, 2020, 38, 5504-5504.	1.6	10
130	Genetic factors associated with prostate cancer conversion from active surveillance to treatment. Human Genetics and Genomics Advances, 2022, 3, 100070.	1.7	10
131	Treatment of prostate cancer metastases: more than semantics. Lancet, The, 2012, 379, 4-6.	13.7	9
132	ER stress in prostate cancer: A therapeutically exploitable vulnerability?. Science Translational Medicine, 2018, 10, .	12.4	9
133	Function of Tumor Suppressors in Resistance to Antiandrogen Therapy and Luminal Epithelial Plasticity of Aggressive Variant Neuroendocrine Prostate Cancers. Frontiers in Oncology, 2018, 8, 69.	2.8	9
134	Retinoic Acid Receptor Activation Reduces Metastatic Prostate Cancer Bone Lesions by Blocking the Endothelial-to-Osteoblast Transition. Cancer Research, 2022, 82, 3158-3171.	0.9	9
135	The case for relevant staging of germ cell tumors. Cancer, 1990, 65, 709-717.	4.1	8
136	New approaches in the treatment of metastatic transitional-cell cancer of the bladder. World Journal of Urology, 1997, 15, 139-143.	2.2	8
137	A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2021, 19, 22-31.e5.	1.9	8
138	Docetaxel in the integrated management of prostate cancer. Current applications and future promise. Oncology, 2002, 16, 63-72.	0.5	8
139	Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohort. OncoImmunology, 2019, 8, e1483303.	4.6	7
140	Re: Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. European Urology, 2013, 64, 170.	1.9	6
141	Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine, 2016, 7, 85-93.	6.1	6
142	Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy. Cancer Chemotherapy and Pharmacology, 2017, 80, 583-589.	2.3	6
143	Determining Clinically Based Factors Associated With Reclassification in the Pre-MRI Era using a Large Prospective Active Surveillance Cohort. Urology, 2020, 138, 91-97.	1.0	6
144	A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. European Journal of Cancer, 2020, 127, 67-75.	2.8	6

#	Article	IF	Citations
145	Impact of a Clinical Trial Initiative on Clinical Trial Enrollment in a Multidisciplinary Prostate Cancer Clinic. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 993-998.	4.9	4
146	Genetic variants of the Wnt signaling pathway as predictors of aggressive disease and reclassification in men with early stage prostate cancer on active surveillance. Carcinogenesis, 2016, 37, 965-971.	2.8	4
147	Measuring the Metabolic Evolution of Glioblastoma throughout Tumor Development, Regression, and Recurrence with Hyperpolarized Magnetic Resonance. Cells, 2021, 10, 2621.	4.1	4
148	Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naÃ¯ve prostate cancer. European Journal of Cancer, 2021, 157, 259-267.	2.8	4
149	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 6-11.	1.9	4
150	Prostate Cancer: Quo Vadis?. European Urology, 2019, 76, 709-711.	1.9	3
151	A phase II trial to evaluate pemetrexed clinical responses in relation to tumor methylthioadenosine phosphorylase (MTAP) gene status in patients with previously treated metastatic urothelial carcinoma.. Journal of Clinical Oncology, 2019, 37, 385-385.	1.6	3
152	Dose Intensity in Germ Cell Tumors: Lessons Learned?. Journal of the National Cancer Institute, 1992, 84, 1686-1687.	6.3	2
153	Molecular determinants of cell death induction following adenovirus-mediated gene transfer of wild-type p53 in prostate cancer cells. International Journal of Cancer, 2001, 91, 159-166.	5.1	2
154	The case for a biologically based classification of prostate cancer. Seminars in Oncology, 2003, 30, 562-566.	2.2	2
155	Prostate cancer bone metastases: not so systemic after all. Lancet Oncology, The, 2014, 15, 675-676.	10.7	2
156	Strategy for the Application of Therapy in Prostate Cancer. Advances in Experimental Medicine and Biology, 2008, 617, 193-199.	1.6	2
157	Chemotherapy resistant transitional cell carcinoma as a target for chemoprevention. Journal of Cellular Biochemistry, 1992, 50, 128-131.	2.6	1
158	Foundation for the integration of biologically based therapy in the management of prostate cancer. Prostate, 2003, 57, 32-38.	2.3	1
159	Re: Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. European Urology, 2010, 57, 728-729.	1.9	1
160	Treatment of Castrate-Resistant Prostate Cancer. Journal of Urology, 2013, 190, 439-440.	0.4	1
161	Modified Logistic Regression Models Using Gene Coexpression and Clinical Features to Predict Prostate Cancer Progression. Computational and Mathematical Methods in Medicine, 2013, 2013, 1-7.	1.3	1
162	Radiotherapy for metastatic prostate cancer. Lancet, The, 2019, 394, 829-830.	13.7	1

#	Article	IF	Citations
163	Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel. JNCI Cancer Spectrum, 2020, 4, pkaa003.	2.9	1
164	Outcomes in men with metastatic castrate-resistant prostate cancer treated with early platinum-based chemotherapy following an unsatisfactory response to androgen receptor (AR) inhibition as part of the phase II dynamic allocation modular sequential (DynAMo) trial.. Journal of Clinical Oncology, 2021, 39, 83-83.	1.6	1
165	Brain metastasis from prostate carcinoma. , 0, .		1
166	Characterization of immune-related adverse events (irAEs) in a phase 3 trial of ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel mCRPC.. Journal of Clinical Oncology, 2014, 32, 52-52.	1.6	1
167	Genome-wide DNA methylation profiling of leukocytes identifies CpG methylation signatures of aggressive prostate cancer. American Journal of Cancer Research, 2021, 11, 968-978.	1.4	1
168	Clinical Challenges for Treatment and a Cure. , 0, , 155-167.		0
169	WHEN â€˜DUELING TECHNOLOGIESâ€™ ARE MISTAKEN FOR PROGRESS. BJU International, 2011, 107, 1699-1700	2.5	0
170	Genetic variants in epithelialâ€“mesenchymal transition genes as predictors of clinical outcomes in localized prostate cancer. Carcinogenesis, 2020, 41, 1057-1064.	2.8	0
171	Reply by Authors. Journal of Urology, 2021, 206, 1156.	0.4	0
172	Analysis of chemotherapy-related modulation of the immune microenvironment in muscle invasive bladder cancer.. Journal of Clinical Oncology, 2020, 38, 5049-5049.	1.6	0
173	Docetaxel in the management of advanced or metastatic urothelial tract cancer. Oncology, 2002, 16, 107-11.	0.5	0
174	Third analysis of a randomized trial of finite abiraterone acetate (AA) plus LHRH agonist (LHRHa) versus LHRHa in biochemically recurrent, non-metastatic hormone-naÃ¯ve prostate cancer (M0HNPC).. Journal of Clinical Oncology, 2022, 40, 135-135.	1.6	0
175	Factors associated with improved outcomes in surgically resectable small cell urothelial cancer (SCUC).. Journal of Clinical Oncology, 2022, 40, 495-495.	1.6	0
176	DynAMo: A dynamic allocation modular sequential trial of approved and promising therapies in men with metastatic CRPC.. Journal of Clinical Oncology, 2022, 40, 5059-5059.	1.6	0